Search results
Showing 661 to 675 of 2208 results for guidelines
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)
Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (HTG388)
Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions.
Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making
Biographies and registered interests for members of the Technology Appraisal Committee C
Using NICE guidance in social work: scenarios for principal social workers
They can help principal social workers (PSWs) understand how to put our guidelines and quality standards into practice. Social care...
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)
Summary of the evidence on delafloxacin for community-acquired pneumonia in adults
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
Getting involved as a voluntary and community sector organisation
Getting involved with NICE as a voluntary and community sector organisation
LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)
NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .
This process guide provides an overview of the key principles used for developing NICE decision aids. It ensures that robust, quality-assured decision aids for people using and providing health and social care services are developed in an open, transparent and timely way, with appropriate input from key groups
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.